Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

100.0%

3 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

3 of 0 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03669549Phase 2Terminated

Nevanimibe HCl for the Treatment of Classic CAH

Role: lead

NCT03053271Phase 2Terminated

A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

Role: lead

NCT02865915Phase 2Terminated

MLE4901 vs. Placebo for the Treatment of PCOS

Role: lead

All 3 trials loaded